Literature DB >> 8740627

Differential susceptibility to neurofibrillary pathology among patients with Down syndrome.

J Wegiel1, H M Wisniewski, J Dziewiatkowski, E R Popovitch, M Tarnawski.   

Abstract

Individual differences in the development of neurofibrillary changes were examined in eight cortical regions in the brains of 43 subjects with Down syndrome (DS; age range, 15-69 years) using sections stained with monoclonal antibodies (mAb) tau-1 and 3-39. Neurofibrillary pathology was found in 4 cases below 36 years of age and in all 20 cases above that age. In the 24 positive cases, numerical density of pretangles stained with tau-1 and 3-39, respectively, was 6.1/mm2 and 0/mm2; early tangles, 5.0/mm2 and 5.3/mm2; mature tangles, 4.0/mm2 and 5.0/mm2 (p < 0.01); and end-stage tangles, 0.04/mm2 and 2.5/mm2 (p < 0.001). Numerical density of pretangles stained with mAb tau-1 and tangles and plaques stained with mAb 3-39 correlates weakly with age (r = 0.43; p< 0.02), and together with the wide range of numerical densities suggested heterogeneity of the population examined. Cluster analysis based on two variables - i.e., numerical density of pretangles stained with mAb tau-1 and neurofibrillary tangles (NFTs) and plaques stained with mAB 3-39, distinguished three groups of subjects with severe, moderate and weak changes. The severely affected group of 5 subject (21%) had an average 54.6/mm2 of neurons and 13.9/mm/ plaques with neurofibrillary changes, whereas the moderately affected group (6 subjects; 25%) showed a significantly lower numerical density of neurons and plaques with neurofibrillary changes (25.7/mm2 and 8.1/mm2, respectively) as compared with the most affected group. Most of the subjects (13; 54%) belong to the third group with only 2.2/mm2 of neurons and 1.4/mm2 plaques with neurofibrillary pathology. Comparison of these three groups of Down syndrome subjects representing high, moderate, and low susceptibility to neurofibrillary changes with the general population suggests that the risk of Alzheimer disease is similar but the onset of pathological changes is earlier in DS.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740627     DOI: 10.1159/000106868

Source DB:  PubMed          Journal:  Dementia        ISSN: 1013-7424


  13 in total

1.  Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-a system: insights for transition to Alzheimer's disease.

Authors:  Fabio Di Domenico; Gilda Pupo; Cesare Mancuso; Eugenio Barone; Francesca Paolini; Andrea Arena; Carla Blarzino; Frederick A Schmitt; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.

Authors:  Jerzy Wegiel; Karol Dowjat; Wojciech Kaczmarski; Izabela Kuchna; Krzysztof Nowicki; Janusz Frackowiak; Bozena Mazur Kolecka; Jarek Wegiel; Wayne P Silverman; Barry Reisberg; Mony Deleon; Thomas Wisniewski; Cheng-Xin Gong; Fei Liu; Tatyana Adayev; Mo-Chou Chen-Hwang; Yu-Wen Hwang
Journal:  Acta Neuropathol       Date:  2008-08-12       Impact factor: 17.088

3.  Maternal choline supplementation differentially alters the basal forebrain cholinergic system of young-adult Ts65Dn and disomic mice.

Authors:  Christy M Kelley; Brian E Powers; Ramon Velazquez; Jessica A Ash; Stephen D Ginsberg; Barbara J Strupp; Elliott J Mufson
Journal:  J Comp Neurol       Date:  2014-04-15       Impact factor: 3.215

4.  Alzheimer's Disease in Adults with Down Syndrome.

Authors:  Warren B Zigman; Darlynne A Devenny; Sharon J Krinsky-McHale; Edmund C Jenkins; Tiina K Urv; Jerzy Wegiel; Nicole Schupf; Wayne Silverman
Journal:  Int Rev Res Ment Retard       Date:  2008-01-01

Review 5.  Exosome release and cargo in Down syndrome.

Authors:  Eric D Hamlett; Angela LaRosa; Elliott J Mufson; Juan Fortea; Aurélie Ledreux; Ann-Charlotte Granholm
Journal:  Dev Neurobiol       Date:  2019-08-06       Impact factor: 3.964

6.  Maternal Choline Supplementation Alters Basal Forebrain Cholinergic Neuron Gene Expression in the Ts65Dn Mouse Model of Down Syndrome.

Authors:  Christy M Kelley; Stephen D Ginsberg; Melissa J Alldred; Barbara J Strupp; Elliott J Mufson
Journal:  Dev Neurobiol       Date:  2019-06-09       Impact factor: 3.964

7.  Effects of Maternal Choline Supplementation on the Septohippocampal Cholinergic System in the Ts65Dn Mouse Model of Down Syndrome.

Authors:  Christy M Kelley; Jessica A Ash; Brian E Powers; Ramon Velazquez; Melissa J Alldred; Milos D Ikonomovic; Stephen D Ginsberg; Barbara J Strupp; Elliott J Mufson
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

Review 8.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

9.  Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain.

Authors:  Fabio Di Domenico; Raffaella Coccia; Annalisa Cocciolo; M Paul Murphy; Giovanna Cenini; Elizabeth Head; D Allan Butterfield; Alessandra Giorgi; Maria Eugenia Schinina; Cesare Mancuso; Chiara Cini; Marzia Perluigi
Journal:  Biochim Biophys Acta       Date:  2013-04-18

10.  Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome.

Authors:  Zhihou Liang; Fei Liu; Khalid Iqbal; Inge Grundke-Iqbal; Jerzy Wegiel; Cheng-Xin Gong
Journal:  J Alzheimers Dis       Date:  2008-04       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.